CN103467526A - Organic metallic platinum compound capable of inhibiting cancer cell proliferation, and synthetic method thereof - Google Patents
Organic metallic platinum compound capable of inhibiting cancer cell proliferation, and synthetic method thereof Download PDFInfo
- Publication number
- CN103467526A CN103467526A CN2013102377582A CN201310237758A CN103467526A CN 103467526 A CN103467526 A CN 103467526A CN 2013102377582 A CN2013102377582 A CN 2013102377582A CN 201310237758 A CN201310237758 A CN 201310237758A CN 103467526 A CN103467526 A CN 103467526A
- Authority
- CN
- China
- Prior art keywords
- platinum compound
- metallic platinum
- synthetic method
- cancer cell
- cell proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an organic metallic platinum compound capable of inhibiting cancer cell proliferation. A synthetic method of the organic metallic platinum compound comprises following steps: organic ligand N, N'-2(2-dimethylamino-ethyl)oxamide L containing N and O hetero atoms is synthesized according to a method disclosed in references; the organic ligand is reacted with K2PtCl4 for 6h at a temperature of 30 DEG C, and the mixture is allowed to stand until the temperature reduces to room temperature, and is filtered; and corresponding crystals [Pt(II)Cl4]<2->.L<2+> are prepared by natural volatilization at room temperature. The organic metallic platinum compound possess obvious inhibition effect on cancer cell proliferation, and can be used as a novel platinum anticarcinogen; the synthetic method is easy for operation, and is convenient for industrialized popularization and application.
Description
Technical field
The present invention relates to a kind of synthetic method of compound, relate in particular to a kind of organo-metallic platinum compound and synthetic method thereof.
Background technology
Since 1967 it is found that cis-platinum has antitumour activity, the application and research of Platinum Anti-tumor Drugs has obtained development rapidly.Today, cis-platinum and carboplatin have become indispensable medicine in cancer chemotherapy.Nineteen ninety-five, the World Health Organization was estimated nearly hundred kinds of cancer therapy drugs in the world, and the comprehensive evaluation scores such as the curative effect of cis-platinum, market occupy first, the row second.According to another statistics, take cis-platinum as leading or having cis-platinum to participate in the 70%-80% that accounts for all chemotherapy regimens of compatibility in China's anticancer chemotherapy treatment plan.
At present, the problem of clinical application platinum kind anti-cancer drugs maximum is resistance, and many patients are congenital or the day after tomorrow platinum kind anti-cancer drugs is produced to resistance, seriously reduced curative effect and the anticancer spectrum of medicine.Cancer cells produces the mechanism of resistance and now thinks that four factors are arranged: 1. reduced the cross-film running of medicine, medicine can not effectively be accumulated in cancer cells; 2. increase the concentration of glutathion inside cell and metallothionein(MT), destroyed the structure of medicine, made it inactivation; 3. strengthen the repairing effect of DNA, the platinum medicine active group that makes to be bonded on the DNA chain dissociates; 4. improve cell to A
2the tolerance of Pt/DNA adducts.Therefore, for above-mentioned mechanism, design and the synthetic platinum medicine that can overcome the cancer cells resistance are the directions of current drug research and development.
Summary of the invention
The object of the present invention is to provide a kind of organo-metallic platinum compound with anticancer increment effect, another purpose is to provide a kind of easy operation, practicable synthetic method.
For achieving the above object, the technical scheme adopted is in the present invention: a kind of organo-metallic platinum compound with anticancer increment effect, and molecular formula is:
The above-mentioned synthetic method with organo-metallic platinum compound of anticancer increment effect is: by existing literature method, synthesize and have the heteroatomic organic ligand N of N, O, N '-bis-(2-dimethylamino-ethyl) oxamide L, then this organic ligand L and K
2ptCl
4under 30 degrees centigrade, reaction is 6 hours, standing to room temperature, filters, and at room temperature volatilization obtains corresponding crystal [Pt (II) Cl naturally
4]
2-l
2+, its synthetic route is as follows:
The present invention has following beneficial effect: show compound [Pt (II) Cl through the experiment contrast
4]
2-l
2+the various kinds of cell strain is all had to restraining effect in various degree, and present the concentration dependent relation, and there is selectivity, especially the increment of hepatoma cell strain Hep G2 had to the strongest restraining effect, its IC
50numerical value reached respectively 22.4 μ M.There is the value-added effect of significant anticancer based on it, can be used as a kind of novel platinum kind anti-cancer drugs and used, overcome the existing problem of cancer therapy drug in the past.Its preparation method is easy to operate in addition, and easily carry out industry and promote and apply, be also the superior part that present technique possesses.
the accompanying drawing explanation
The IC50 numerical value figure that Fig. 1 is compound 1 and 2 pairs of five kinds of cell strains.
embodiment
(1) by existing method, synthesized there is N, the heteroatomic organic ligand N of O, N '-bis-(2-dimethylamino-ethyl) oxamide (L);
(2) by this organic ligand L and K
2ptCl
4under 30 degrees centigrade, react respectively 6 hours, standing to room temperature, filter, at room temperature volatilization obtains corresponding crystal naturally, and synthetic route is as follows:
Utilize X-ray diffraction to carry out crystal structure analysis, result shows that its crystalline structure can be expressed as respectively [Pt (II) Cl
4]
2-l
2+.
And then there is the half-inhibition concentration (IC of the organo-metallic platinic compound of clear and definite structure to human A549 cell lines, mouse leukemia cell strain P388, human cervical carcinoma cell Hela, human breast cancer cell MCF-7 and five kinds of cell strains of liver cancer cell Hep G2 more than having studied
50), as shown in Figure 1.
Result shows, two compounds all have restraining effect in various degree to five kinds of cell strains, and present the concentration dependent relation, and have selectivity, wherein the increment of hepatoma cell strain Hep G2 are had to the strongest restraining effect, its IC
50numerical value reached 22.4 μ M.
Claims (2)
1. the organo-metallic platinum compound with anticancer increment effect, its molecular formula is:
2. a method for preparing above-mentioned organo-metallic platinum compound, is characterized in that: by existing literature method, synthesize and have the heteroatomic organic ligand N of N, O, N '-bis-(2-dimethylamino-ethyl) oxamide L, then this organic ligand L and K
2ptCl
4under 30 degrees centigrade, reaction is 6 hours, standing to room temperature, filters, and at room temperature volatilization obtains corresponding crystal [Pt (II) Cl naturally
4]
2-l
2+.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102377582A CN103467526A (en) | 2013-06-16 | 2013-06-16 | Organic metallic platinum compound capable of inhibiting cancer cell proliferation, and synthetic method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102377582A CN103467526A (en) | 2013-06-16 | 2013-06-16 | Organic metallic platinum compound capable of inhibiting cancer cell proliferation, and synthetic method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103467526A true CN103467526A (en) | 2013-12-25 |
Family
ID=49792594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102377582A Pending CN103467526A (en) | 2013-06-16 | 2013-06-16 | Organic metallic platinum compound capable of inhibiting cancer cell proliferation, and synthetic method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103467526A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060616A (en) * | 1996-07-22 | 2000-05-09 | Hoffmann-La Roche Inc. | Bis-platinum complexes with polymethylene derivatives as ligands having antitumor activity |
| US6130245A (en) * | 1998-10-26 | 2000-10-10 | Unitech Pharmaceuticals, Inc. | Dinuclear platinum complexes as cisplatin analogs for cancer treatment |
| CN1315326A (en) * | 2000-03-31 | 2001-10-03 | 邵佳驹 | Cisplatinun dinuclear platinum complex for treating cancer and its therapeutic method |
| US20020165204A1 (en) * | 1999-04-21 | 2002-11-07 | Unitech Pharmaceuticals, Inc. | Carboplatin analogs for cancer treatment |
-
2013
- 2013-06-16 CN CN2013102377582A patent/CN103467526A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060616A (en) * | 1996-07-22 | 2000-05-09 | Hoffmann-La Roche Inc. | Bis-platinum complexes with polymethylene derivatives as ligands having antitumor activity |
| US6130245A (en) * | 1998-10-26 | 2000-10-10 | Unitech Pharmaceuticals, Inc. | Dinuclear platinum complexes as cisplatin analogs for cancer treatment |
| US20020165204A1 (en) * | 1999-04-21 | 2002-11-07 | Unitech Pharmaceuticals, Inc. | Carboplatin analogs for cancer treatment |
| CN1315326A (en) * | 2000-03-31 | 2001-10-03 | 邵佳驹 | Cisplatinun dinuclear platinum complex for treating cancer and its therapeutic method |
Non-Patent Citations (1)
| Title |
|---|
| LUIGI MESSORI等，: "Structural Features of a New Dinuclear Platinum(II) Complex with Significant Antiproliferative Activity", 《INORGANIC CHEMISTRY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilton-Ely et al. | Multimetallic assemblies using piperazine-based dithiocarbamate building blocks | |
| Martínez-Lillo et al. | Rhenium (IV) compounds inducing apoptosis in cancer cells | |
| Al-Jaroudi et al. | Synthesis, characterization and cytotoxicity of new gold (III) complexes with 1, 2-diaminocyclohexane: Influence of stereochemistry on antitumor activity | |
| CN103450281A (en) | 1-azabenzanthrone-platinum (II) complex as well as synthesis method and application thereof | |
| CN101838284A (en) | Dibutyltin oxide coordination compound and preparation method and application thereof | |
| CN105713047A (en) | Platinum (II) coordination complex and preparing method and application thereof | |
| CN101289467A (en) | Platinum salts of organic acids, preparation thereof and applications in preparation of anticancer drugs | |
| CN103509059A (en) | Cyclometalated ruthenium complex, and preparation method and application thereof | |
| Xu et al. | Antitumor platinum (II) complexes of N-cyclobutyl-1R, 2R-diaminocyclohexane with dicarboxylates as leaving groups | |
| WO2012155559A1 (en) | Organic hybridized tetra-core platinum complex and preparation method thereof as well as the use thereof in manufacturing medicament for antitumor | |
| CN105481902B (en) | Platinum (IV) anticancer compound using dihydrogen phosphate as axial ligand | |
| CN110128482B (en) | Preparation method and application of novel Pt (IV) complex with tumor targeting function | |
| Liu et al. | Synthesis and antiproliferative activity of (1 R, 2 R)-N 1-(2-butyl)-1, 2-cyclohexanediamine platinum (II) complexes with malonate derivatives | |
| CN103467526A (en) | Organic metallic platinum compound capable of inhibiting cancer cell proliferation, and synthetic method thereof | |
| CN101830933A (en) | Novel method for synthesizing antitumor medicament platinum | |
| CN101386629B (en) | Water-soluble Pt(II) anticancer complexes using 3-acetoxy-1,1-cyclobutane dicarboxylic acid radical as leaving group | |
| Bergamini et al. | New PTA (1, 3, 5-triaza 7-phosphaadamantane) derivatives associating zwitterionic structure and coordinative ability | |
| Enos et al. | Substitution of aqua ligands from alkyldiamine-bridged dinuclear Pt (II) complexes using azole nucleophiles | |
| CN103435657A (en) | Organic metal platinum compound with anti-cancer effect, and synthesis method thereof | |
| CN111747889B (en) | NNO type quinoline Fe (II) complex containing multiple coordination sites and preparation method and application thereof | |
| Yu et al. | Design, synthesis and biological evaluation of six dinuclear platinum (II) complexes | |
| CN1948323A (en) | Platinum (II)- anticancer compound using 2-hydroxy-1,3-propane diamine as carrier group | |
| CN102924488A (en) | Structure, preparation method and purpose of silver-containing pyrazine Schiff base complex | |
| Xing et al. | Synthesis and cytotoxicity of diam (m) ineplatinum (II) complexes with 2, 2-bis (hydroxymethyl) malonate as the leaving group | |
| WO2021051709A1 (en) | Osmium complex, preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Xiuling Inventor after: Song Yulan Inventor after: Zhu Baoyong Inventor after: Zhang Yongzheng Inventor before: Zhang Xiuling |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG XIULING TO: ZHANG XIULING SONG YULAN ZHU BAOYONG ZHANG YONGZHENG |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131225 |
|
| RJ01 | Rejection of invention patent application after publication |